Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
PLSE 
Pulse Biosciences Inc (PLSE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/17/2025: PLSE (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -6.13% | Avg. Invested days 27 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.01B USD | Price to earnings Ratio - | 1Y Target Price 5 |
Price to earnings Ratio - | 1Y Target Price 5 | ||
Volume (30-day avg) - | Beta 1.63 | 52 Weeks Range 10.52 - 25.00 | Updated Date 06/29/2025 |
52 Weeks Range 10.52 - 25.00 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.99 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -43.61% | Return on Equity (TTM) -77.86% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 903787838 | Price to Sales(TTM) 60.23 |
Enterprise Value 903787838 | Price to Sales(TTM) 60.23 | ||
Enterprise Value to Revenue 64.63 | Enterprise Value to EBITDA -1.81 | Shares Outstanding 67273904 | Shares Floating 17434021 |
Shares Outstanding 67273904 | Shares Floating 17434021 | ||
Percent Insiders 74 | Percent Institutions 8.64 |
Upturn AI SWOT
Pulse Biosciences Inc
Company Overview
History and Background
Pulse Biosciences, Inc. was founded in 2009. The company focuses on developing and commercializing a proprietary Nano-Pulse Stimulation (NPS) technology platform for a variety of medical applications.
Core Business Areas
- Dermatology: Development and commercialization of NPS-based solutions for dermatological conditions, primarily for skin revitalization and lesion clearance.
- Oncology: Research and development of NPS for treating cancer and tumors.
- Veterinary: Development and commercialization of NPS-based solutions for animal health conditions.
Leadership and Structure
Kevin Danahy serves as the President and CEO. The company operates with a functional structure, with teams dedicated to research, development, clinical affairs, regulatory affairs, and commercialization.
Top Products and Market Share
Key Offerings
- CellFX System: The CellFX System is designed for dermatologic procedures that require the non-thermal ablation of cells, primarily used for skin revitalization. Market share is still developing, with main competitors being companies providing laser and radiofrequency treatments. The company is working on expanding the applications of CellFX to include the treatment of seborrheic keratoses (SKs).
- NPS Platform: The NPS platform, a foundational technology, is used to develop various applications in dermatology, oncology, and veterinary medicine. Revenue generation is currently primarily derived from the CellFX System.
Market Dynamics
Industry Overview
The medical aesthetics market is experiencing significant growth, driven by increased demand for non-invasive and minimally invasive procedures. The oncology market continues to expand, with significant unmet needs for targeted therapies. The veterinary medicine market is expanding with higher costs for pet care.
Positioning
Pulse Biosciences is positioned as an innovator in the medical technology space, leveraging its unique NPS technology to address unmet needs in dermatology and oncology. Their competitive advantage lies in the non-thermal mechanism of action of NPS, which allows for targeted cell ablation with minimal damage to surrounding tissues.
Total Addressable Market (TAM)
The total addressable market (TAM) for medical aesthetics is expected to reach USD 28.7 billion by 2027. The oncology market is significantly larger. Pulse Biosciences is positioned to capture a portion of this market through its CellFX System and future applications of the NPS platform.
Upturn SWOT Analysis
Strengths
- Proprietary Nano-Pulse Stimulation (NPS) technology
- Potential for non-thermal and targeted cell ablation
- Expanding applications in dermatology and oncology
- Strong intellectual property portfolio
Weaknesses
- Limited commercial traction and revenue generation
- Dependence on successful development and regulatory approval of new applications
- Cash burn and need for additional financing
- Relatively small size compared to larger competitors
Opportunities
- Expanding the CellFX System into new dermatological applications
- Advancing NPS technology for oncology treatments
- Potential partnerships and collaborations with larger medical device companies
- Geographic expansion into international markets
Threats
- Competition from established players in the medical aesthetics market
- Regulatory hurdles and delays in obtaining approvals
- Technological advancements by competitors
- Economic downturn and reduced consumer spending on elective procedures
Competitors and Market Share
Key Competitors
- CUTI
- ZBH
- ALGN
Competitive Landscape
Pulse Biosciences faces competition from established players in the medical aesthetics and oncology markets. Its competitive advantage lies in its proprietary NPS technology, which offers a unique mechanism of action for targeted cell ablation. However, it needs to establish greater commercial traction.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to being in early stage of revenue generation. Much of its value has been on potential rather than historicals.
Future Projections: Future growth is dependent on the commercial success of the CellFX System and other applications of the NPS technology. Analyst estimates vary widely depending on the successful execution of the company's strategy.
Recent Initiatives: Recent initiatives include expanding the commercialization of the CellFX System, conducting clinical trials for new applications of NPS, and strengthening its intellectual property portfolio.
Summary
Pulse Biosciences is an early-stage medical technology company with a unique NPS technology platform. The company is focused on dermatology, oncology, and veterinary medicine. While its technology holds promise, it faces significant challenges in commercialization, regulatory approvals, and competition. Success hinges on expanding the CellFX System and developing new applications of NPS.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings, third-party market research reports, analyst estimates, news articles.
Disclaimers:
This analysis is for informational purposes only and should not be considered as financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share figures are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pulse Biosciences Inc
Exchange NASDAQ | Headquaters Miami, FL, United States | ||
IPO Launch date 2016-05-18 | President, CEO, Principal Executive Officer, Principal Financial Officer & Co-Chairman of the Board Mr. Paul Arthur LaViolette | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 75 | Website https://www.pulsebiosciences.com |
Full time employees 75 | Website https://www.pulsebiosciences.com | ||
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; CellFX nsPFA Percutaneous Electrode system for soft tissue ablation in surgical setting; CellFX nsPFA Cardiac Clamp designed for use in surgical treatment of atrial fibrillation (AF); CellFX nsPFA 360° Cardiac Catheter designed to provide a circumferential, or circular, ablation in a single treatment cycle; and The CellFX Consol, a tunable, software-enabled, and console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.